Serial hypoxia imaging with 99mTc-HL91 SPECT to predict radiotherapy response in nonsmall cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 6, 2006, Pages 628-633

  Li, Ling ^a   Yu, Jinming ^a   Xing, Ligang ^a   Ma, Kefeng ^b   Zhu, Hui ^a   Guo, Hongbo ^a   Sun, Xindong ^a   Li, Jianbin ^a   Yang, Guoren ^a   Li, Wanlong ^a   Yue, Jinbo ^a   Li, Baosheng ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b CHINA AEROSPACE SCIENCE AND INDUSTRY CORPORATION   (China)

Author keywords

HL91; Hypoxia; Nonsmall cell lung cancer; Prognosis; Radiotherapy; SPECT

Indexed keywords

CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL; UPENAZIME TC 99M;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; HYPOXIA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; OXYGENATION; RADIATION RESPONSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; OXIMES; OXYGEN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RADIOTHERAPY, CONFORMAL; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TREATMENT OUTCOME;

EID: 33845495384     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000242345.71582.e0     Document Type: Conference Paper

References (21)

1. Menon C, Fraker DL. Tumor oxygenation status as a prognostic marker. Cancer Lett. 2005;22:225-235.
2. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett. 2003;195:1-16.
3. Harrison LB, Chadha M, Hill RJ. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist. 2002;7:492-508.
4. Brizel DM, Scully SP, Harrelson JM, et al. Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Res. 1996;56:5347-5350.
5. Lartigau E, Lusinchi A, Weeger P, et al. Variations in tumor oxygen tension (pO2) during accelerated radiotherapy of head and neck carcinoma. Eur J Cancer. 1998;34:856-861.
6. Olive PL, Banath JP, Aquino-Parsons C. Measuring hypoxia in solid tumors - is there a gold standard? Acta Oncol. 2001;40:917-923.
7. Nordsmark M, Loncaster J, Aquino-Parsons C, et al. Measurement of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas. Radiother Oncol. 2003;67:35-44.
8. Chapman JD, Zanzonico P, Ling CC. On measuring hypoxia in individual tumors with radiolabeled agents. J Nucl Med. 2001;42:1653-1655.
9. 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection. Int J Radiat Oncol Biol Phys. 1998;42:737-740.
10. Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med. 2001;31:321-329.
11. Cook GJ, Houston S, Barrington SF, et al. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J Nucl Med. 1998;39:99-103.
12. Gronroos T, Bentzen L, Marjamaki P, et al. Comparison of the biodistribution of 2 hypoxia markers [18F] FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:513-520.
13. Buscombe JR, Bombardieri E. Imaging cancer using single photon techniques. Q J Nucl Med Mol Imaging. 2005;49:121-131.
14. 99mTc-HL91 "hot spot" imaging of mice bearing human carcinoma by gamma camera and the effects of tumor necrosis on imaging. Chin Med J (Engl). 2000;113:404-407.
15. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with (F-18)fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199-212.
16. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using (F-18) fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;33:391-398.
17. Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in nonsmall cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253-260.
18. 60Cu-ATSM: relationship to therapeutic response - a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233-1238.
19. Lehtio K, Eskola O, Viljanen T, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;59:971-982.
20. 99mTc-HL91(4,9- diaza-3,3,10,10- tetramethyldodecan-2,11-dione dioxime). Ann Nucl Med. 2003;179:131-138.
21. Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49:1171-1182.